Tumor type M2 pyruvate kinase expression in gastric cancer, colorectal cancer and controls

Table 1 Concentration of tumor M₂-PK and common clinical status in 54 patients with gastric cancer

No.	Tumor M2-PKstage (U/mL)	TNM	Metastasis	No.	Tumor M2-PK (U/mL)	TNM stage	Metastasis
1	9.26	II	N	28	24.52	IIIB	M
2	36.5	IIIA	N	29	16.6	II	M
3	23.08	II	N	30	9.26	II	N
4	23.08	IIIB	M	31	37.85	IA	N
5	165.3	IIIA	M	32	17.06	II	N
6	18.06	II	N	33	34.81	IIIA	M
7	8.81	II	N	34	14.81	II	N
8	17.34	II	N	35	23.49	II	M
9	6.87	IB	M	36	28.25	IIIA	M
10	17.91	IIIB	M	37	12.87	II	N
11	24.07	IIIB	M	38	10.62	II	M
12	12.67	II	N	39	118.02	IV	M
13	28.4	IIIB	M	40	28.75	IIIA	N
14	56.76	IIIA	N	41	14.31	II	M
15	6.42	IIIA	M	42	32.4	II	M
16	28.7	IIIB	M	43	7.61	II	N
17	7.47	IA	N	44	12.23	IA	N
18	13.9	IIIA	M	45	18.1	II	M
19	14.5	II	M	46	25.17	IIIA	M
20	69.24	IIIB	M	47	10.63	II	N
21	12.33	IIIA	M	48	8.84	II	N
22	28.66	IIIB	M	49	19.35	IIIA	N
23	136.6	IV	M	50	41.11	II	M
24	11.36	II	N	51	11.38	IIIA	N
25	7.62	II	N	52	21.75	IIIA	M
26	17.2	IB	N	53	30.03	IIIB	M
27	11.36	IIIA	M	54	11.3	II	N

N = non metastasis, M = metastasis.